TUBERKULYOZNING ZAMONAVIY EPIDEMIOLOGIYASI VA PROFILAKTIKA CHORALARI
- Authors
-
-
Gulmurotova Dilafruz Shoymardonovna
Toshkent Davlat Tibbiyot Universisteti mikrobiologiya virusologiya va immunologiya kafedrasi assistenti:
Author
-
Xoliqberdiyev Javohir Akmal o‘g‘li
Toshkent Davlat tibbiyot universiteti (Toshkent, Oʻzbekiston) TDTU 1-son davolash ishi fakultet talabalari
Author
-
- Keywords:
- Array
- Abstract
- Ushbu maqolada tuberkulyozning zamonaviy epidemiologik holatini va profilaktika choralarini tahlil qilish maqsadida adabiyotlar asosida sharhlangan.Tuberkulyoz hozirgi vaqtda ham jahon miqyosida keng tarqalgan va o‘limga olib keluvchi infeksion kasalliklardan biri hisoblanadi. Mycobacterium tuberculosis tomonidan qo‘zg‘atiluvchi ushbu kasallik asosan o‘pka to‘qimasini zaharlaydi, ammo boshqa organlarni ham zaharlashi mumkin. Zamonaviy epidemiologik ma’lumotlar shuni ko‘rsatadiki, dunyoda yiliga taxminan 10 million yangi tuberkulyoz shtammlari qayd etiladi va 1.3 million kishi vafot etadi. Kasallikning tarqalishida ijtimoiy-iqtisodiy omillar, immunitet tanqisligi, HIV infeksiyasi hamda doriga bardoshli shtammlarning paydo bo‘lishi muhim rol o‘ynaydi. Profilaktika choralari orasida erta aniqlash, DOTS strategiyasini qo‘llash, vaksinatsiya va epidemiologik nazorat choralarini kuchaytirish asosiy o‘rinni egallaydi.
- References
-
1.Bates M.N., Khalakdina A., Pai M. Risk of tuberculosis from exposure to tobacco smoke // Archives of Internal Medicine. 2007. Vol. 167(4). P. 335-342.
2.Bell L.C.K., Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection // Nature Reviews Microbiology. 2018. Vol. 16(2). P. 80-93.
3.Cambier C.J., Falkow S., Ramakrishnan L. Host evasion and exploitation schemes of Mycobacterium tuberculosis // Cell. 2014. Vol. 159(7). P. 1497-1509.
4.Chakravorty S., Simmons A.M., Rowneki M. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis // Clinical Microbiology Reviews. 2017. Vol. 30(3). P. 737-760.
5.Cole S.T., Brosch R., Parkhill J. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence // Nature. 1998. Vol. 393(6685). P. 537-544.
6.Dean A.S., Zignol M., Cabibbe A.M. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data // PLoS Medicine. 2020. Vol. 17(1). P. e1003008.
7.Dheda K., Barry C.E., Maartens G. Tuberculosis // Lancet. 2016. Vol. 387(10024). P. 1211-1226.
8.Ernst J.D. The immunological life cycle of tuberculosis // Nature Reviews Immunology. 2012. Vol. 12(8). P. 581-591.
9.Floyd K., Glaziou P., Zumla A., Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB Strategy // Lancet Respir Med. 2018. Vol. 6(4). P. 299-314.
10.Frieden T.R., Munsiff S.S. The DOTS strategy for controlling the global tuberculosis epidemic // Clinics in Chest Medicine. 2005. Vol. 26(2). P. 197-205.
11.Getahun H., Matteelli A., Chaisson R.E., Raviglione M. Latent Mycobacterium tuberculosis infection // New England Journal of Medicine. 2015. Vol. 372(22). P. 2127-2135.
12.Horton K.C., MacPherson P., Houben R.M. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries // PLOS Medicine. 2016. Vol. 13(9). P. e1002119.
13.Houben R.M., Dodd P.J. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling // PLoS Medicine. 2016. Vol. 13(10). P. e1002152.
14.Lönnroth K., Jaramillo E., Williams B.G., Dye C., Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants // Social Science & Medicine. 2009. Vol. 68(12). P. 2240-2246.
15.MacNeil A., Glaziou P., Sismanidis C. Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets - 2017 // MMWR Morb Mortal Wkly Rep. 2019. Vol. 68(11). P. 263-266.
16.O'zbekiston Respublikasi Sog'liqni saqlash vazirligi. Tuberkulyoz bo'yicha statistik ma'lumotlar. Toshkent: 2023. 15b.
17.Pai M., Behr M.A., Dowdy D., Dheda K. Tuberculosis // Nature Reviews Disease Primers. 2016. Vol. 2. P. 16076.
18.Palomino J.C., Martin A., Camacho M. Rapid culture-based methods for drug-resistance detection // Expert Review of Molecular Diagnostics. 2007. Vol. 7(5). P. 569-580.
19.Pawlowski A., Jansson M., Sköld M. Tuberculosis and HIV Co-Infection // PLoS Pathogens. 2012. Vol. 8(2). P. e1002464.
20.Pontali E., Raviglione M.C., Migliori G.B. Drug-resistant tuberculosis: Current challenges and future perspectives // European Respiratory Journal. 2019. Vol. 53(4). P. 1900423.
21.Smith G.S., Schoenbach V.J., Richardson D.B., Gammon M.D. Particulate air pollution and susceptibility to the development of pulmonary tuberculosis // Epidemiology. 2014. Vol. 25(6). P. 849-856.
22.Steingart K.R., Henry M., Ng V. Fluorescence versus conventional sputum smear microscopy for tuberculosis // Cochrane Database Syst Rev. 2006. Vol. (4). P. CD006880.
23.Volmink J., Garner P. Directly observed therapy for treating tuberculosis // Cochrane Database of Systematic Reviews. 2007. Vol. (4). P. CD003343.
24.World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO Press; 2023. 68p.
25.World Health Organization. Global tuberculosis report 2023. Geneva: WHO Press; 2023. 52p.
- Downloads
- Published
- 2026-05-05
- Section
- Articles